Schistosomiasis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Schistosomiasis – Pipeline Review, H2 2016’, provides an overview of the Schistosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Schistosomiasis

The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects

The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Schistosomiasis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Schistosomiasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Kancera AB

LondonPharma Ltd

Merck KGaA

Salvensis

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Schistosomiasis Overview 6

Therapeutics Development 7

Pipeline Products for Schistosomiasis - Overview 7

Pipeline Products for Schistosomiasis - Comparative Analysis 8

Schistosomiasis - Therapeutics under Development by Companies 9

Schistosomiasis - Therapeutics under Investigation by Universities/Institutes 10

Schistosomiasis - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Schistosomiasis - Products under Development by Companies 13

Schistosomiasis - Products under Investigation by Universities/Institutes 14

Schistosomiasis - Companies Involved in Therapeutics Development 15

Kancera AB 15

LondonPharma Ltd 16

Merck KGaA 17

Salvensis 18

Schistosomiasis - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 24

BDM-I - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

EDE-1102 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

intestinal schistosomiasis vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

intestinal schistosomiasis vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

L-Praziquantel - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecule for Schistosomiasis - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecule for Schistosomiasis - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules for Schistosomiasis - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Schistosomiasis - Dormant Projects 34

Schistosomiasis - Product Development Milestones 35

Featured News & Press Releases 35

Aug 23, 2013: BioDiem US patent for skin and wound infections 35

Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites 35

Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I 35

Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I 36

Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for Schistosomiasis, H2 2016 7

Number of Products under Development for Schistosomiasis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Schistosomiasis – Pipeline by Kancera AB, H2 2016 15

Schistosomiasis – Pipeline by LondonPharma Ltd, H2 2016 16

Schistosomiasis – Pipeline by Merck KGaA, H2 2016 17

Schistosomiasis – Pipeline by Salvensis, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Schistosomiasis – Dormant Projects, H2 2016 34

List of Figures

List of Figures

Number of Products under Development for Schistosomiasis, H2 2016 7

Number of Products under Development for Schistosomiasis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports